What PT-141 Means
PT-141 is a development name commonly used for bremelanotide. FDA approval belongs to the finished prescription product Vyleesi: a defined bremelanotide formulation and autoinjector, not to every vial sold online under the PT-141 name.[1]
The approved indication is acquired, generalized hypoactive sexual desire disorder that causes marked distress or interpersonal difficulty in premenopausal women and is not due to another medical or psychiatric condition, relationship problems, or a medication or drug substance. It is not indicated for men, postmenopausal women, or enhancement of sexual performance.[1]
Mechanism
Bremelanotide is a melanocortin-receptor agonist. The current label states that the exact mechanism by which it improves HSDD symptoms is unknown.[1] Describing it as a central melanocortin drug is reasonable; claiming a proven pathway for libido, erectile function, or performance is not.
What the Trials Showed
Two phase 3 randomized, double-blind, placebo-controlled trials in the labeled population supported statistically significant changes in prespecified sexual-desire and distress measures.[2] The label also states that there was no significant between-group difference in the change in satisfying sexual events, a secondary endpoint.[1]
The evidence supports the narrow approved population and product. It does not establish efficacy for erectile dysfunction, men, postmenopausal women, generalized libido enhancement, or an unverified compounded product.
Labelled Safety Information
The current Vyleesi label lists nausea, flushing, injection-site reactions, headache, and vomiting among the most common adverse reactions. Nausea occurred in 40% of treated patients in phase 3 trials, required antiemetic treatment in 13%, and led 8% to discontinue.[1]
The product is contraindicated in uncontrolled hypertension or known cardiovascular disease. It transiently raises blood pressure and lowers heart rate, may cause focal hyperpigmentation that does not always resolve, can slow gastric emptying, and can substantially reduce oral naltrexone exposure. Pregnancy, contraception, renal or hepatic impairment, and other warnings are product-label matters requiring clinician review.[1]
Approved Product Versus Online Vials
Vyleesi remains an FDA-approved prescription drug under NDA 210557, with current labeling published through DailyMed.[1] That status is specific to the reviewed active ingredient, strength, excipients, device, manufacturing controls, indication, and conditions of use.
A compounded or research-grade product marketed as PT-141 is not automatically equivalent to Vyleesi. Compounded drugs are not FDA-approved and FDA does not verify their safety, effectiveness, or quality before marketing.[3]